- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02738632
Efficacy and Safety of TAH Combination in Comparison With Telmisartan/Amlodipine Combination for Essential Hypertension Patients
Randomized, Double-Blind, Multi-Center, Phase 3 Trial to Evaluate the Efficacy and Safety of Telmisartan/Amlodipine/Hydrochlorothiazide Combination in Comparison With Telmisartan/Amlodipine Combination for Essential Hypertension Patients Not Controlled by Telmisartan/Amlodipine Combination
Study Overview
Status
Conditions
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of
- Seoul National University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 19 years old or above Koreans living in Korea
Patients with uncontrolled essential hypertension at screening time(Visit 1)
- Naïve: 160 mmHg ≤ sitSBP < 200 mmHg
- Use antihypertensive drugs:140 mmHg ≤ sitSBP < 200 mmHg
Patients with uncontrolled hypertension after Telmisartan/Amlodipine 40/5mg treatment for 6 weeks at randomization(Visit 2)
- 140 mmHg ≤ sitSBP < 200 mmHg
- Patients who agreed to participate in the trial
Exclusion Criteria:
Test results showing the following values at screening time(Visit 1)
- The change of mean sitSBP ≥ 20 mmHg or sitDBP ≥ 10 mmHg on target arm between 1st and 2nd measurement
- screening time(Visit 1), time of randomization(Visit 2): sitDBP ≥ 120 mmHg
- Patients with secondary blood pressure or suspected of secondary blood pressure (for example,aortic coarctation, primary aldosteronism, renal artery stenosis, pheochromocytoma)
-Patients with congestive heart failure(NYHA class III~IV)
- Patients with unstable angina or myocardial infarction or valvular heart disease within 6 months prior to study entry
- Patients who have severe ventricular tachycardia, atrial fibrillation, atrial flutter or clinically significant arrhythmia
- Patients who have history of cerebrovascular disease as cerebral infarction, cerebral hemorrhage within 6 months prior to study entry
- Type I Diabets Mellitus or Type II Diabetes Mellitus with HbA1c > 9%
- Patients who have history of severe or malignant retinopathy within 6 months prior to study entry
- Patients who suspected of Renal dysfunction that may affect the absorption, distribution, metabolism or excretion (Serum Creatinine :> 2mg/dL ), gastrointestinal, haematological, liver disease (AST or ALT > 2.5 times of upper limit of normal range)
- Patients who should be administered antihypertensive drugs other than clinical trial medication(Diuretics, β-blockers, ACE inhibitors, Angiotensin II Receptor Blocker, Calcium Channel Blockers, α-blockers, Renin Inhibitors, Vasodilators)
- Patients who should be administered medications prohibited for concomitant use during study period
- Patients who are dependent on drugs or alcohol
- Patients with surgical and medical disease that may affect the absorption, distribution, metabolism or excretion
- Patients with hypersensitivity to the components of investigational drug.
- Patients with hypersensitivity to Sulfonamide
- Patients with anuria
- Patients with hypercalcemia, hyponatremia/hypokalemia
- Patients with Addison's disease
- Patients who have hereditary problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption
- Patients with any chronic or accute inflammation disease needed to chronic inflammation therapy
- History of malignant tumor including leukemia, lymphoma within 5 years
- Patients taking other clinical trial drugs within 30 days from the time of visit for screening
- Pregnancy, breast-feeding, or child-bearing potential Patients
- Patients who are judged unsuitable to participate in this study by investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Telmisartan/Amlodipine+Hydrochlorothiazide
Telmisartan/Amlodipine combination drug and Hydrochlorothiazide
|
Treatment1:Telmisartan/Amlodipine 40/5mg 1 Tab.and Hydrochlorothiazide 12.5mg 1 Tab.QD Treatment2: Telmisartan/Amlodipine 40/5mg 2 Tab.and Hydrochlorothiazide 25mg 1 Tab.QD |
Active Comparator: Telmisartan/Amlodipine
Telmisartan/Amlodipine combination drug and Placebo for Hydrochlorothiazide
|
Treatment1:Telmisartan/Amlodipine 40/5mg 1 Tab.and Hydrochlorothiazide 12.5mg Placebo 1 Tab.QD Treatment2: Telmisartan/Amlodipine 40/5mg 2 Tab.and Hydrochlorothiazide 25mg Placebo 1 Tab.QD |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The change of sitting systolic blood pressure
Time Frame: From baseline at week 8
|
From baseline at week 8
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The change of sitting systolic blood pressure
Time Frame: From baseline at week 2
|
From baseline at week 2
|
The change of sitting diastolic blood pressure
Time Frame: From baseline at week 2 and 8
|
From baseline at week 2 and 8
|
The ratio of subjects who get normalized blood pressure
Time Frame: at week 2 and 8
|
at week 2 and 8
|
Response Rate
Time Frame: at week 2 and 8
|
at week 2 and 8
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Hypertension
- Essential Hypertension
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Vasodilator Agents
- Natriuretic Agents
- Membrane Transport Modulators
- Diuretics
- Calcium-Regulating Hormones and Agents
- Calcium Channel Blockers
- Angiotensin II Type 1 Receptor Blockers
- Angiotensin Receptor Antagonists
- Sodium Chloride Symporter Inhibitors
- Amlodipine
- Hydrochlorothiazide
- Telmisartan
- Telmisartan amlodipine combination
Other Study ID Numbers
- ID-TAH-301
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Essential Hypertension
-
Addpharma Inc.Completed
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Cytos Biotechnology AGCompletedMild Essential Hypertension | Moderate Essential HypertensionSwitzerland
-
Sulaiman AlRajhi CollegesUnknownHypertension, Essential | β-hydroxybutyrate
-
BayerCompletedHypertension, EssentialGermany
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
Addpharma Inc.Not yet recruitingHypertension,Essential
-
Instituto de Cardiologia do Rio Grande do SulRecruitingHypertension | Hypertension,EssentialBrazil
-
Federal University of Health Science of Porto AlegreIrmandade Santa Casa de Misericórdia de Porto Alegre; Leonhardt Ventures LLCNot yet recruitingHypertension | Hypertension,Essential
Clinical Trials on Telmisartan/Amlodipine+Hydrochlorothiazide
-
Yonsei UniversityCompleted
-
IlDong Pharmaceutical Co LtdCompleted
-
Boehringer IngelheimCompleted
-
Yuhan CorporationNot yet recruitingEssential HypertensionKorea, Republic of
-
Boehringer IngelheimCompletedHypertensionItaly, Germany, Netherlands, France, South Africa, Belgium, Denmark, Finland, Ireland, Spain
-
Yuhan CorporationCompleted
-
IlDong Pharmaceutical Co LtdCompleted
-
Boehringer IngelheimCompletedHypertensionUnited States, Bulgaria, Czech Republic, France, Hungary, Korea, Republic of, Romania, Russian Federation, Slovakia, Spain, Ukraine